ZGNX News and Press, Zogenix Inc. From 12/01/20

New long-term safety, efficacy, and durability data for FINTEPLA® (fenfluramine) oral solution in Dravet syndrome Full results from Phase 3 study of FINTEPLA in Lennox-Gastaut syndrome New d ata from investigator-initiated stud y in C...

Zogenix just launched Fintepla, a product to treat Dravet syndrome. GW Pharma already has a Fintepla competitor Epidiolex approved and growing big sales in Dravet syndrome and other indications that Fintepla will likely expand to. Zogenix’s major sell-off makes its valuatio...

EMERYVILLE, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and CEO, and Michael P. Smith, Executive Vice President, CFO, ...

Zogenix, Inc. (ZGNX) Q3 2020 Earnings Conference Call November 09, 2020, 04:30 PM ET Company Participants Brian Ritchie - LifeSci Advisors Stephen Farr - CEO Ashish Sagrolikar - CCO Michael Smith - CFO Conference Call Participants Roanna Ruiz - SVB Leerink Eddie Hickman - Guggenheim Securitie...

Image source: The Motley Fool. Zogenix Inc (NASDAQ: ZGNX) Q3 2020 Earnings Call Nov 9, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: Zogenix Inc (ZGNX) Q3 2020 Earnings Call Transcript

Zogenix (ZGNX): Q3 GAAP EPS of -$1.08 misses by $0.08.Revenue of $2.86M (+354.0% Y/Y) beats by $0.51M.The Company had $525.2M in cash, equivalents, and marketable securities, reflecting the issuance of a $200M convertible bond on September 28, 2020.Shares -2.60%.Press Release For further de...

FINTEPLA ® (fenfluramine) oral solution launched in the U.S. in late July for Dravet syndrome with high enrollment of physicians and patients into the FINTEPLA Risk Evaluation and Mitigation Strategy (REMS) program More than 300 patients prescribed FINTE...

Zogenix (NASDAQ:ZGNX) is scheduled to announce Q3 earnings results on Monday, November 9th, after market close.The consensus EPS Estimate is -$0.93 (+86.2% Y/Y) and the consensus Revenue Estimate is $2.35M (+273.0% Y/Y).Over the last 2 years, ZGNX has beaten EPS estimates 25% of the time and ...

EMERYVILLE, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it has changed the date of its previously announced earnings release and earnings call. The Company will now report ...

EMERYVILLE, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the three and nine months ended September 30, 2020 and host a corporate upd...